Former shareholders of Genzyme Corp.’s Biosurgery Division and their counsel at Boies, Schiller & Flexner won a "major legal victory" when a New York federal judge ruled their case against Genzyme could go forward. According to the plaintiffs, Genzyme’s CEO and directors manipulated the price of Biosurgery shares in order to trade them for Genzyme shares at an advantageous rate that underpaid shareholders.
